172 related articles for article (PubMed ID: 33570057)
1. Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis.
Li B; Feng F; Jia H; Jiang Q; Cao S; Wei L; Zhang Y; Lu J
Food Funct; 2021 Mar; 12(6):2404-2417. PubMed ID: 33570057
[TBL] [Abstract][Full Text] [Related]
2. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
Shao Z; Li Y; Dai W; Jia H; Zhang Y; Jiang Q; Chai Y; Li X; Sun H; Yang R; Cao Y; Feng F; Guo Y
Pharmacol Res; 2018 Sep; 135():188-200. PubMed ID: 30114438
[TBL] [Abstract][Full Text] [Related]
3. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
[TBL] [Abstract][Full Text] [Related]
4. TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs.
Wang H; Chu F; Zhang XF; Zhang P; Li LX; Zhuang YL; Niu XF; He X; Li ZJ; Bai Y; Mao D; Liu ZW; Zhang DL; Li BA
Cell Death Dis; 2023 Jan; 14(1):64. PubMed ID: 36707511
[TBL] [Abstract][Full Text] [Related]
5. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
[TBL] [Abstract][Full Text] [Related]
6. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor.
Li J; Zhao J; Wang H; Li X; Liu A; Qin Q; Li B
Onco Targets Ther; 2018; 11():5885-5894. PubMed ID: 30271172
[TBL] [Abstract][Full Text] [Related]
8. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
9. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
11. miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway.
Shao QP; Wei C; Yang J; Zhang WZ
Onco Targets Ther; 2020; 13():7213-7227. PubMed ID: 32801751
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
[TBL] [Abstract][Full Text] [Related]
13. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
14. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
15. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7.
Tang X; Yang W; Shu Z; Shen X; Zhang W; Cen C; Cao L; Zhang M; Zheng S; Yu J
Oncol Rep; 2019 Feb; 41(2):1231-1237. PubMed ID: 30535501
[TBL] [Abstract][Full Text] [Related]
17. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
18. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
19. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
[TBL] [Abstract][Full Text] [Related]
20. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis.
Yang H; Ren L; Wang Y; Bi X; Li X; Wen M; Zhang Q; Yang Y; Jia Y; Li Y; Zang A; Wei Y; Dai G
Cell Death Dis; 2020 Oct; 11(10):851. PubMed ID: 33051436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]